Macrocure Seeks to Go Global Using Cell Therapy for Wounds
By Marie Powers
Staff Writer
Staff Writer
Wednesday, June 19, 2013
The potential value of cell therapy in wound care applications grabbed the attention of the biotech world last fall when Smith & Nephew plc, of London, picked up Fort Worth, Texas-based Healthpoint Biotherapeutics for $782 million in cash on the strength of its cell therapy product, HP802-247, in wound care.
To continue reading subscribe now to Latest News
Learn More about Latest News
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.